Leptin revisited: its mechanism of action and potential for treating diabetes

被引:229
作者
Coppari, Roberto [1 ,2 ,3 ]
Bjorboek, Christian [4 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hypothalam Res, Dallas, TX 75390 USA
[2] Univ Geneva, Fac Med, Dept Cellular Physiol & Metab, CH-1211 Geneva, Switzerland
[3] Univ Calif Irvine, Ctr Epigenet & Metab, Irvine, CA 92697 USA
[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Endocrinol & Metab, Sch Med,Dept Med, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
DIET-INDUCED OBESITY; ACTIVATED-RECEPTOR-GAMMA; BLOOD-BRAIN-BARRIER; HYPOTHALAMIC PROOPIOMELANOCORTIN NEURONS; REGULATES GLUCOSE-HOMEOSTASIS; FAMILIAL PARTIAL LIPODYSTROPHY; INCREASES INSULIN SENSITIVITY; CENTRAL MELANOCORTIN SYSTEM; RECOMBINANT HUMAN LEPTIN; FASTING PLASMA-GLUCOSE;
D O I
10.1038/nrd3757
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Since the discovery of leptin in 1994, we now have a better understanding of the cellular and molecular mechanisms underlying its biological effects. In addition to its established anti-obesity effects, leptin exerts antidiabetic actions that are independent of its regulation of body weight and food intake. In particular, leptin can correct diabetes in animal models of type 1 and type 2 diabetes. In addition, long-term leptin replacement therapy improves glycaemic control, insulin sensitivity and plasma triglycerides in patients with severe insulin resistance due to lipodystrophy. These results have spurred enthusiasm for the use of leptin therapy to treat diabetes. Here, we review the current understanding of the glucoregulatory functions of leptin, emphasizing its central mechanisms of action and lessons learned from clinical studies, and discuss possible therapeutic applications of leptin in the treatment of type 1 and type 2 diabetes.
引用
收藏
页码:692 / 708
页数:17
相关论文
共 216 条
[1]   A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy [J].
Agarwal, AK ;
Garg, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :408-411
[2]   Role of leptin in the neuroendocrine response to fasting [J].
Ahima, RS ;
Prabakaran, D ;
Mantzoros, C ;
Qu, DQ ;
Lowell, B ;
MaratosFlier, E ;
Flier, JS .
NATURE, 1996, 382 (6588) :250-252
[3]   Dominant Role of the p110β Isoform of PI3K over p110α in Energy Homeostasis Regulation by POMC and AgRP Neurons [J].
Al-Qassab, Hind ;
Smith, Mark A. ;
Irvine, Elaine E. ;
Guillermet-Guibert, Julie ;
Claret, Marc ;
Choudhury, Agharul I. ;
Selman, Colin ;
Piipari, Kaisa ;
Clements, Melanie ;
Lingard, Steven ;
Chandarana, Keval ;
Bell, Jimmy D. ;
Barsh, Gregory S. ;
Smith, Andrew J. H. ;
Batterham, Rachel L. ;
Ashford, Michael L. J. ;
Vanhaesebroeck, Bart ;
Withers, Dominic J. .
CELL METABOLISM, 2009, 10 (05) :343-354
[4]   Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence [J].
Apostolova, Nadezda ;
Blas-Garcia, Ana ;
Esplugues, Juan V. .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (20) :2130-2144
[5]   Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter [J].
Auernhammer, CJ ;
Bousquet, C ;
Melmed, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6964-6969
[6]  
Bagnol D, 1999, J NEUROSCI, V19
[7]   Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[8]   Leptin receptor signaling in is required for normal body POW neurons weight homeostasis [J].
Balthasar, N ;
Coppari, R ;
McMinn, J ;
Liu, SM ;
Lee, CE ;
Tang, V ;
Kenny, CD ;
McGovern, RA ;
Chua, SC ;
Elmquist, JK ;
Lowell, BB .
NEURON, 2004, 42 (06) :983-991
[9]   Activation of downstream signals by the long form of the leptin receptor [J].
Banks, AS ;
Davis, SM ;
Bates, SH ;
Myers, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (19) :14563-14572
[10]   Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible [J].
Banks, WA ;
Farrell, CL .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 285 (01) :E10-E15